Additionally, STING pathway agonists targeting CD44 and PD-L1 have been shown to increase the expression of type I interferons in the TME and facilitate the recruitment of CD8 + T cells and NK cells to tumor sites, aiding in overcoming resistance to TNBC immunotherapy [11, 167] (Fig. 3). This evidence concerns the gene CD8A and neoplasm.